DEM names Grmusa CEO, Quéva CSO

Longwood-backed oncology company DEM BioPharma Inc. named Nenad Grmusa as CEO, Christophe Quéva as CSO, and Loise Francisco-Anderson as SVP and head of biology. Grmusa, who succeeds co-founder David Donabedian, joins from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) where he was SVP, head of R&D strategy and external innovation. Quéva was CSO and SVP of research at Oncorus Inc. (NASDAQ:ONCR), and Francisco-Anderson was VP of discovery, innovation and oncology at Evelo Biosciences Inc. (NASDAQ:EVLO).

5AM Ventures added Arthur Tzianabos and June Lee as venture partners. Tzianabos was president and CEO of Homology Medicines Inc. (NASDAQ:FIXX), a 5AM portfolio company, before which he was SVP of research and early development at Shire plc. Lee was COO, EVP and chief development officer of MyoKardia Inc., which was acquired by Bristol Myers Squibb Co. (NYSE:BMY) in a $13.1 billion deal. The company also named Joseph Loscalzo as venture adviser. Loscalzo is a professor at Harvard Medical School and chair of the Department of Medicine and physician-in-chief at Brigham and Women’s Hospital...